In T2D mice, the SGLT-2 inhibitor empagliflozin and the DPP-4 inhibitor linagliptin used alone or in combination enhance the levels of markers associated with glomerular autophagy and contribute to the recovery of autophagy, thus reducing the damage to the kidney in diabetes (Korbut et al., 2020). Here, SLC5A2 is linked to type 2 diabetes mellitus.